Literature DB >> 16855462

Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders.

Simon J C Davies1, Sean D Hood, Spilios V Argyropoulos, Kelly Morris, Caroline Bell, Harry J Witchel, Peter R Jackson, David J Nutt, John P Potokar.   

Abstract

Serotonin-promoting drugs show cardioprotective properties in patients with anxiety or depression, but it is not known if this is a direct effect of increasing serotonin. We aimed to characterize the effect of serotonin manipulation through acute tryptophan depletion on cardiovascular and psychological responses to stress challenge in recovered patients with anxiety disorders. In 27 recovered patients with anxiety disorders (panic disorder treated by selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy, social anxiety disorder treated by SSRIs), we performed a double-blind randomized crossover study. On 2 separate days, the subjects ingested an acute tryptophan-depleting (aTD) or nondepleting (nD) drink in random order and underwent a stress challenge at time of maximum depletion. Systolic blood pressure (P = 0.007; diff = 9.0 mm Hg; 95% confidence interval (CI), 2.6-15.3 mm Hg) and diastolic blood pressure (P = 0.032; diff = 5.7 mm Hg; 95% CI, 0.6-10.9 mm Hg) responses to stress were significantly greater under aTD than nD, as were the psychological responses to stress (for Spielberger state anxiety, difference in stress response between aTD and nD = 7.11; P = 0.025). Blood pressure responses to stress showed no correlation with psychological responses. The significant increases in acute stress sensitivity in both cardiovascular and psychological domains on serotonin depletion suggest that serotonin is involved in the control of both cardiovascular and psychological aspects of the acute stress response. The lack of correlation in the difference between aTD and nD conditions in cardiovascular and psychological responses suggests that serotonin may have distinct effects on these 2 domains, rather than the cardiovascular responses being merely a secondary consequence of psychological changes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855462     DOI: 10.1097/01.jcp.0000227704.79740.c0

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

1.  Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al.

Authors:  Sean D Hood; Simon J C Davies; David J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2008-12-13       Impact factor: 4.530

2.  Population differences in associations of serotonin transporter promoter polymorphism (5HTTLPR) di- and triallelic genotypes with blood pressure and hypertension prevalence.

Authors:  Redford B Williams; George D Bishop; Brett C Haberstick; Andrew Smolen; Beverly H Brummett; Ilene C Siegler; Michael A Babyak; Xiaodong Zhang; E Shyong Tai; Jeannette Jen-Mai Lee; Maudrene Tan; Yik Ying Teo; Shiwei Cai; Edmund Chan; Carolyn Tucker Halpern; Eric A Whitsel; Shawn Bauldry; Kathleen Mullan Harris
Journal:  Am Heart J       Date:  2016-12-29       Impact factor: 4.749

3.  Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion.

Authors:  Abigail A Marsh; Elizabeth C Finger; Beata Buzas; Niveen Soliman; Rebecca A Richell; Meena Vythilingham; Daniel S Pine; David Goldman; R J R Blair
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

Review 4.  Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications.

Authors:  Bernardo Sousa-Pinto; Manuel J Ferreira-Pinto; Mário Santos; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 5.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

6.  Dystrophic serotonin axons in postmortem brains from young autism patients.

Authors:  Efrain C Azmitia; Jorawer S Singh; Xiao P Hou; Jerzy Wegiel
Journal:  Anat Rec (Hoboken)       Date:  2011-09-08       Impact factor: 2.064

7.  Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder.

Authors:  Sean D Hood; Dana A Hince; Simon J C Davies; Spilios Argyropoulos; Hayley Robinson; John Potokar; David J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

8.  The Effects of Tryptophan Enhancement and Depletion on Plasma Catecholamine Levels in Healthy Individuals.

Authors:  Stephen H Boyle; Beverly H Brummett; Cynthia M Kuhn; John C Barefoot; Ilene C Siegler; Redford B Williams; Anastasia Georgiades
Journal:  Psychosom Med       Date:  2019-01       Impact factor: 4.312

9.  Impact of acute tryptophan depletion on mood and eating-related urges in bulimic and nonbulimic women.

Authors:  Kenneth R Bruce; Howard Steiger; Simon N Young; N M K Ng Ying Kin; Mimi Israël; Mélissa Lévesque
Journal:  J Psychiatry Neurosci       Date:  2009-09       Impact factor: 6.186

10.  Tryptophan research in panic disorder.

Authors:  Eduard Maron; Jakov Shlik; David J Nutt
Journal:  Int J Tryptophan Res       Date:  2008-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.